| Field | Specification |
|---|---|
| Target | |
| Alternative names | Nuclear receptor coactivator 1; NCoA-1; Class E basic helix-loop-helix protein 74; bHLHe74; Protein Hin-2; RIP160; Renal carcinoma antigen NY-REN-52; Steroid receptor coactivator 1; SRC-1; NCOA1; SRC1 |
| UniProt # | |
| Host | |
| Clone | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthesized peptide derived from human KAT13A / SRC1 Nuclear receptor coactivator that directly binds nuclear receptors and stimulates the transcriptional activities in a hormone-dependent fashion. Involved in the coactivation of different nuclear receptors, such as for steroids (PGR, GR and ER), retinoids (RXRs), thyroid hormone (TRs) and prostanoids (PPARs) . |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Liquid |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
Clone AEHD-14 is a rabbit monoclonal antibody that recognizes nuclear receptor coactivator 1 (gene NCOA1) in human samples and is validated for Western blot, IHC and immunoprecipitation. The predicted molecular weight is 156.8 kDa, and the supplier reports an observed band at about 157 kDa.
NCOA1 (SRC-1) is a member of the p160 steroid receptor coactivator family. It binds ligand-activated nuclear receptors, including those for steroids, thyroid hormone, retinoids and PPARs, as well as several STAT factors, and assembles coactivator complexes that remodel chromatin to boost transcription. It is studied in hormone signaling, metabolism and hormone-dependent cancers.
| Target | Nuclear receptor coactivator 1 (gene NCOA1; UniProt Q15788, human) |
|---|---|
| Clone | AEHD-14 |
| Host / Clonality / Isotype | Rabbit / Monoclonal / Rabbit IgG |
| Reactivity | Human |
| Form | Liquid |
| Formulation | PBS (pH 7.4); 150 mM NaCl; 0.02% sodium azide; 50% glycerol; plus stabilizers |
| Calculated MW | 156.8 kDa |
| Observed MW | 157 kDa |
| Storage | Long term: −20 °C for up to 12 months. Frequent use: 4 °C for up to 1 month. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 1:500–1:2000 |
|---|---|
| Immunohistochemistry | 1:50–1:200 |
| Immunoprecipitation | 1:50 |
Samples with a confirmed band (WB): human 293T cells, human HEL cells, human K562 cells, human RT4 whole cellIHC: human breast cancer tissue.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 8% SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 1: 500 overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Immunogen
Synthetic peptide based on the sequence of human KAT13A / SRC1 Nuclear receptor coactivator that directly binds nuclear receptors and stimulates the transcriptional activities in a hormone-dependent fashion.
Reactivity Notes
The supplier lists reactivity with human. UniProt places nuclear receptor coactivator 1 in the nucleus. Tissue expression noted by UniProt (human): Widely expressed. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
